Healthcare Costs and Resource Use Among Chronic Low-Back Pain Patients Treated With Belbuca or Buprenorphine Transdermal Patches: A Retrospective US Medicare Claims Analysis

Abstract

Conclusion: This study demonstrated lower total cLBP-related and any-cause outpatient costs with fewer cLBP-related outpatient visits and favorable healthcare cost trends in Belbuca as compared with buprenorphine patch patients.